Insight

Armando Orlandi: ASCO25 Breast Cancer Update – Early Data from May 30th Session

Armando Orlandi/photos.asco.org

Jun 1, 2025, 08:04

Armando Orlandi: ASCO25 Breast Cancer Update – Early Data from May 30th Session

Armando Orlandi, Medical Director at the Agostino Gemelli University Hospital Foundation IRCCS, posted on LinkedIn:

“ASCO25 Breast Cancer Update: Early Data from May 30th Session

Several preliminary studies presented today warrant careful consideration, though longer follow-up and larger cohorts will be essential for validation:

EMERGING TARGETED APPROACHES:

• PF-07248144 (KAT6 inhibitor): Early signals with 37.2% ORR in ER+/HER2- mBC post-CDK4/6i – preliminary data supporting Phase 3 initiation

• Sac-TMT (TROP2 ADC): Initial first-line results showing 70.7% ORR in a/mTNBC – requires validation in larger randomized studies

• Trastuzumab-pkrb + gedatolisib: Early efficacy (43.2% ORR) in heavily pretreated HER2+ mBC with PIK3CA mutations – small cohort data

INTRACRANIAL ACTIVITY SIGNALS:

• SHR-A1811: Early intracranial activity data (84.4% ORR monotherapy, 72.7% + bevacizumab) in small HER2+ brain mets cohort – promising but needs mature survival data

• Adebrelimab + bevacizumab + cisplatin/carboplatin: Preliminary CNS activity (77.1% ORR) in TNBC brain mets – encouraging initial OS trends require longer observation

TREATMENT OPTIMIZATION INSIGHTS:

• Ribociclib + trastuzumab + letrozole: Early first-line data (30.4-month mPFS) suggests potential for chemotherapy-sparing approaches in HR+/HER2+ disease – single-arm study limitations
• Trastuzumab deruxtecan rechallenge: Real-world safety data supports clinical practice after G1 ILD – though patient selection remains critical

DIAGNOSTIC AND DISPARITIES CONSIDERATIONS:

• AI-assisted HER2 pathology: Initial training improvements in HER2-low/ultralow scoring accuracy – implementation challenges remain

• HER2+ ADC outcome disparities: Real-world data confirms persistent racial gaps (Asian 89.5% vs Black 80.9% 5-year survival) – systematic barriers need addressing

While these early results show promise, definitive conclusions await mature data, randomized comparisons, and broader validation. The preliminary nature of many findings underscores the need for continued investigation.

This session exemplifies the iterative nature of oncological research – each data point, however early, contributes to our evolving understanding. The continuous progression from bench to bedside, through phases of clinical development, reflects the relentless pursuit of better outcomes that defines our field.

Today’s preliminary signals may become tomorrow’s standard of care, but only through rigorous validation and the collective effort of the global research community.

Tracking emerging evidence in oncology | Early data requires cautious interpretation.”

Read OncoDaily’s Special Articles about ASCO 2025:

Highlights from ASCO 2025 Day 1

Highlights from ASCO 2025 Day 2

ASCO